Public domain

Tools are available for public use without current copyright or licensing restrictions, primarily published by Federal, State, or local governments.

Your Words Matter – Language Showing Compassion and Care for Women, Infants, Families, and Communities Impacted by Substance Use Disorder

This resource offers background information and tips for providers on how to use person-first language and on which terms to avoid using to reduce stigma and negative bias when discussing addiction or substance use disorder with pregnant women and mothers.

MaineMOM

MaineMOM aims to improve care for pregnant and postpartum people with opioid use disorder and their infants by integrating maternal and substance use treatment services.

Medications for Alcohol Use FAQ

Alcohol is the third leading cause of preventable death in the United States, making it a key public health issue. This document is designed to provide information and answer common questions primary care clinicians may have about medications prescribed for the treatment of alcohol use disorder.

The FDA SOURCE Model

The primary objectives of the SOURCE (Simulation of Opioid Use, Response, Consequences, and Effects) model are threefold: help the FDA and other stakeholders identify high-impact opioid-related interventions, assess potential unanticipated consequences of potential policies, and identify needs for further research.

Safe Use of Benzodiazepines: Clinical, Regulatory, and Public Health Perspectives

This two-day public workshop convened regulators, academic researchers, clinicians, patient advocates, and other stakeholders to share information underlying this action and gather input related to the safe use of benzodiazepines.

NIH HEAL Initiative

The Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, is an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis.

Margolis-FDA Workshop: Identifying Key Competencies for Opioid Prescriber Education

This was a two-day virtual public workshop (which can now be re-watched) that focused on identifying gaps in existing opioid prescriber education offerings and core competencies that should be included in educational content for opioid prescribers and other healthcare providers, including prescriber education under a Risk Evaluation and Mitigation Strategy (REMS).

FDA Public Workshop on Opioid Prescriber Education

This was a two-day virtual public workshop (which can now be re-watched) that convened regulators, clinical researchers, providers, patient advocates, and other stakeholders to exchange information and obtain input by discussing prescriber education's potential role in alleviating the evolving opioid and substance use crisis.

Food and Drug Administration Overdose Prevention Framework

The FDA Overdose Prevention Framework consists of four overarching priorities that align with the U.S. Department of Health & Human Services' Overdose Prevention Strategy to address the public health emergency as it continues to evolve.

Vital Signs: Drug Overdose Deaths, by Selected Sociodemographic and Social Determinants of Health Characteristics — 25 States and the District of Columbia, 2019-2020

This report describes changes in drug overdose death rates from 2019 to 2020, stratified by sex, age group, and race and ethnicity. In addition, it examines differences in circumstances surrounding drug overdose, and assesses differences in overdose death rates by county-level income inequality and availability of mental health treatment providers and providers of medications for opioid use disorder.

Subscribe to Public domain